Drug repositioning for gynecologic tumors: a new therapeutic strategy for cancer

TheScientificWorldJournal
Kouji BannoDaisuke Aoki

Abstract

The goals of drug repositioning are to find a new pharmacological effect of a drug for which human safety and pharmacokinetics are established and to expand the therapeutic range of the drug to another disease. Such drug discovery can be performed at low cost and in the short term based on the results of previous clinical trials. New drugs for gynecologic tumors may be found by drug repositioning. For example, PPAR ligands may be effective against ovarian cancer, since PPAR activation eliminates COX-2 expression, arrests the cell cycle, and induces apoptosis. Metformin, an antidiabetic drug, is effective for endometrial cancer through inhibition of the PI3K-Akt-mTOR pathway by activating LKB1-AMPK and reduction of insulin and insulin-like growth factor-1 due to AMPK activation. COX-2 inhibitors for cervical cancer may also be examples of drug repositioning. PGE2 is induced in the arachidonate cascade by COX-2. PGE2 maintains high expression of COX-2 and induces angiogenic factors including VEGF and bFGF, causing carcinogenesis. COX-2 inhibitors suppress these actions and inhibit carcinogenesis. Combination therapy using drugs found by drug repositioning and current anticancer drugs may increase efficacy and reduce adverse drug ...Continue Reading

References

Dec 15, 1991·The New England Journal of Medicine·M J ThunC W Heath
Jul 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J T ThigpenC Evers
Jan 1, 1996·Annual Review of Cell and Developmental Biology·T LembergerW Wahli
Apr 5, 2001·International Journal of Radiation Oncology, Biology, Physics·D K GaffneyM Dodson
Sep 27, 2001·Proceedings of the National Academy of Sciences of the United States of America·J R Testa, A Bellacosa
Jan 17, 2002·The Journal of Pathology·Bastiaan P van ReesG Johan A Offerhaus
Mar 20, 2002·The Journal of Biological Chemistry·Kotha SubbaramaiahAndrew J Dannenberg
Jul 3, 2002·Nature Reviews. Cancer·Igor Vivanco, Charles L Sawyers
Aug 16, 2002·Annals of Oncology : Official Journal of the European Society for Medical Oncology·G FerrandinaG Scambia
Sep 28, 2002·International Immunopharmacology·Xia Zhang, Howard A Young
Jun 26, 2003·The Journal of Biological Chemistry·F Gregory BuchananRaymond N DuBois
Jun 27, 2003·The Journal of Biological Chemistry·Kotha SubbaramaiahAndrew J Dannenberg
Oct 11, 2003·Obstetrics and Gynecology·Walter H GotliebGilad Ben-Baruch
Apr 10, 2004·Carcinogenesis·Christopher J NicolFrank J Gonzalez
Sep 24, 2004·Gynecologic Oncology·Pedro T RamirezCharles Levenback
Oct 2, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J Tate ThigpenShu Liao
Mar 17, 2005·Journal of the National Cancer Institute·Gary M CliffordUNKNOWN Swiss HIV Cohort
Apr 26, 2005·BMJ : British Medical Journal·Josie M M EvansAndrew D Morris
Aug 2, 2005·Obstetrics and Gynecology·UNKNOWN American College of Obstetricians and Gynecologists
Nov 19, 2005·Science·Maria Domenica CastelloneJ Silvio Gutkind
Aug 2, 2006·Clinical Lymphoma & Myeloma·Chris Schwab, Sundar Jagannath
Oct 13, 2006·Neoplasia : an International Journal for Oncology Research·Sara VignatiCarlo V Catapano
Feb 10, 2007·The Lancet Oncology·Claire Tilstone
Feb 10, 2007·The Lancet Oncology·Lynne Kincaid
Apr 14, 2007·Molecular Cancer Therapeutics·Yoshihito YokoyamaHideki Mizunuma
Dec 26, 2007·Pathology Oncology Research : POR·Bing XinHideki Mizunuma
Jan 18, 2008·Proceedings of the National Academy of Sciences of the United States of America·Dipak PanigrahyMark W Kieran

❮ Previous
Next ❯

Citations

Feb 26, 2016·Tissue Engineering. Part B, Reviews·Soojung LeeJeong Ik Lee
Aug 1, 2015·PLoS Neglected Tropical Diseases·Gordana PanicJennifer Keiser
Jul 6, 2016·Critical Reviews in Oncology/hematology·Angiolo GadducciMartina Gallo
Nov 29, 2017·Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology·E SahinC Saatci
Jan 17, 2019·Journal of Pathology and Translational Medicine·Hyo Jeong KangEunsil Yu
May 21, 2020·Diagnostic Cytopathology·Konstantinos KosmasAnna Marouga
Jun 14, 2018·Scientific Reports·Bassam M AyoubShaker A Mousa
Oct 12, 2018·Gynecologic Oncology·Anil Belur NagarajAnalisa DiFeo
Jun 3, 2021·Cancers·Ya-Hui ChenYi-Hsuan Hsiao
Nov 18, 2021·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Jennifer Chae-KimClifford C Hayslip

❮ Previous
Next ❯

Methods Mentioned

BETA
chips
hysterectomy

Related Concepts

Related Feeds

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Related Papers

European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)
Mathilde JalvingElisabeth G E de Vries
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Guilherme Z RochaJosé B C Carvalheira
© 2022 Meta ULC. All rights reserved